Browse by Vaccine Status

This page shows data for Phase 3 Vaccine Status.
Total Entries Retrieved: 62
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10313 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 CanSino Biologics Inc. 2020 China 18 years and above Single dose Intramuscular NA NA NA NA NA NA PakVac, Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) NA NCT04526990 https://clinicaltrials.gov/show/NCT04526990 NA
10314 Nanocovax COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Nanogen Pharmaceutical Biotechnology JSC 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular Aluminum Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04922788 https://clinicaltrials.gov/show/NCT04922788 NA
10315 Omicron COVID-19 Vaccine (Vero Cell), Inactivated COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 China National Biotec Group Company Limited 2020 China NA NA Intramuscular NA NA NA NA NA NA NA NA NA http://www.chictr.org.cn/showproj.aspx?proj=62581 https://covid-19pharmacovigilance.paho.org/sinopharmbibp
10316 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Laboratorio Elea Phoenix S.A. 2020 Argentina 18 - 85 years 2 doses 21 days apart Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 HB02 strain NA NA NA NA NA NA NCT04560881 https://clinicaltrials.gov/show/NCT04560881 NA
10317 Inactivated SARS-CoV-2 vaccine (Vero cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Health Institutes of Turkey 2020 Turkey 18 - 59 years 2 doses 14 days apart Intramuscular NA SARS-CoV-2 virus antigenic protein NA NA NA NA NA NA NCT04582344 https://clinicaltrials.gov/show/NCT04582344 NA
10318 Covidful COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Chinese Academy of Medical Sciences 2021 China 18 years and above 2 doses 2 weeks apart Intramuscular NA NA NA NA Institute of Medical Biology Brazil, Malaysia IMBCAMS COVID-19 vaccine NA NCT04659239 https://clinicaltrials.gov/show/NCT04659239 https://clinicaltrials.gov/ct2/show/NCT05164731
10319 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 3 doses on day 0, 21 and 42 Intramuscular Aluminum (aluminium hydroxide) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04887207 https://clinicaltrials.gov/show/NCT04887207 https://clinicaltrials.gov/ct2/show/NCT04530656
10320 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04860258 https://clinicaltrials.gov/ct2/show/NCT04860258?term=NCT04860258&draw=2&rank=1 NA
10321 WIBP-CorV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Sinopharm, Wuhan Institute of Biological Products 2021 China 18 years and above 2 doses 21 days apart Intramuscular NA SARS-CoV-2 whole virus NA NA G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co. Ltd, Beijing Institute of Biological Products Co Ltd. China, UAE Zhongkangkewei 33816047 NCT04510207 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04510207
10322 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 CanSino Biologics Inc. NA China NA Single dose Intramuscular NA NA NA NA Beijing Institute of Biotechnology NA Adenovirus type 5 vector 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10323 BNT162b1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 BioNTech SE, Pfizer Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NCT04368728 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04368728
10324 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-Further-Expands-INNOVATE-Phase-3-Trial-for-COVID-19-DNA-Vaccine-Candidate-INO-4800-With-Regulatory-Authorization-from-India/default.aspx
10325 INO-4800 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 Inovio Pharmaceuticals 2021 USA 18 years and above 2 doses 28 days apart Intradermal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.isrctn.com/ISRCTN15779782
10326 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. NA NA NA 2 doses 21 days apart Intramuscular Matrix-M1 Spike protein of SARS-CoV-2 virus NA NA NA NA TAK-019, SARS-CoV-2 rS 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10327 Covaxin COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Bharat Biotech International Limited NA India NA 2 doses 14 days apart Intramuscular NA NA NA NA NA NA BBV152 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10328 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 Israel Institute for Biological Research 2021 Israel 18 - 55 years NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Weizmann Institute of Science NA IIBR-100 33937326 NCT04990466 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10329 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 ReiThera Srl 2021 Italy 18 years and above 2 doses 21 days apart Intramuscular Replication defective Simian Adenovirus (GRAd) encoding S Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NCT04791423 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10330 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 Janssen Vaccines & Prevention B.V. NA NA 18 years and above NA Intramuscular NA NA NA NA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10331 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG 2021 Belgium 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein mRNA based vaccine NA NA NA CVnCoV 33816047 NCT04860258 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10332 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Research Institute for Biological Safety Problems 2021 Kazakhstan 18 years and above 2 doses 28 days apart Intramuscular NA NA NA NA NA NA QazCovid-in 33816047 NCT04691908 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10333 AG0301-COVID19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 AnGes Inc. 2021 Japan 18 years and above 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Japan Agency for Medical Research and Development NA NA 33816047 NCT04655625 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10334 AWcorna COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Academy of Military Sciences, Walvax Biotechnology Co. Ltd. 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus mRNA based vaccine NA NA NA Walvax COVID-19 vaccine, ARCoV NA NCT04847102 https://delta.larvol.com/products/?ProductId=4355caae-8746-469c-ab52-0b40ddfde811&Index=0 NA
10335 ARCT-154 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 Vinbiocare Biotechnology Joint Stock Company 2021 Vietnam 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Arcturus Therapeutics Inc. NA VBC-COV19-154 NA NCT05012943 https://clinicaltrials.gov/ct2/show/NCT05012943 NA
10336 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 AstraZeneca plc 2021 Brazil 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 variant strain B.1.351 NA NA NA Brazil, UK, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NCT04973449 https://clinicaltrials.gov/ct2/show/NCT04973449 NA
10337 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals 2021 Australia 18 years and above 2 doses 21 days apart Intramuscular AS03, CpG 1018, alum Spike protein of SARS-CoV-2 virus NA NA GlaxoSmithKline, Dynavax NA NA 33816047 NCT04672395 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10338 Covifenz COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 3 Medicago Inc NA NA NA 2 doses 21 days apart Intramuscular NA NA NA NA NA NA CoVLP 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10339 UB-612 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Vaxxinity 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10340 Recombinant SARS-CoV-2 vaccine (Sf9 Cell) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 West China Hospital, Sichuan University 2021 China 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10341 AZD1222 (ChAdOx1) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Virus like particle Phase 3 Janssen Pharmaceutical NA NA 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10342 WIBP-CorV COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Wuhan Institute of Biological Products NA NA 18 - 59 years Single dose Intramuscular NA Inactivated SARS-CoV-2 virus NA NA NA NA NVX-CoV2373 33402220 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ NA
10343 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur, GlaxoSmithKline 2021 USA 18 years and above 2 doses 14 days apart Intramuscular NA SARS-CoV-2 protein NA NA GlaxoSmithKline USA, Colombia, Honduras, Japan, Kenya VAT00002, VAT00008 NA NCT04904549 https://clinicaltrials.gov/ct2/show/NCT04904549 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10344 CVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA RNA based vaccine Phase 3 CureVac AG NA Germany NA NA Intramuscular NA NA mRNA based vaccine NA NA Germany, Cuba, Peru CVnCoV NA NCT04674189 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04674189
10345 CoV2 preS dTM-AS03 vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur NA NA NA NA Intramuscular NA NA Recombinant EMA NA NA NA NA NCT04904549 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04762680
10346 SCB-2019 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Clover Biopharmaceuticals NA Australia NA NA Intramuscular NA NA Novel recombinant SARSCoV-2 Spike trimer fusion protein NA NA Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, Philippines, Poland NA NA NCT04405908 https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://clinicaltrials.gov/ct2/show/NCT04405908
10347 COVIran Barekat COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Shifa Pharmed Industrial Co. 2021 Iran 18 - 75 years 2 doses 28 days apart Intramuscular NA NA NA NA NA NA BIV1-CovIran, COVIran Barkat NA NA http://en.irct.ir/trial/54881 https://en.irct.ir/trial/52701
10348 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 ReiThera Srl NA Italy 18 years and above 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04791423 https://clinicaltrials.gov/show/NCT04791423 NA
10349 Vidprevtyn COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Sanofi Pasteur 2021 USA 18 years and above 2 doses 21 days apart Intramuscular AS03 SARS-CoV-2 protein NA US FDA GlaxoSmithKline NA VAT00002, VAT00008 NA NCT04762680 https://clinicaltrials.gov/show/NCT04762680 https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
10350 Skycovion COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 SK Bioscience Co. Ltd. 2021 South Korea 19 - 85 years 2 doses 28 days apart Intramuscular AS03 Recombinant SARS-CoV-2 protein NA NA International Vaccine Institute, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations NA GBP510 NA NCT04750343 https://clinicaltrials.gov/show/NCT04750343 NA
10351 QazVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Research Institute for Biological Safety Problems 2020 Kazakhstan 18 years and above 2 doses 21 days apart Intramuscular NA NA NA NA NA NA QazCovid-in NA NCT04691908 https://clinicaltrials.gov/show/NCT04691908 NA
10352 Covovax (Nuvaxovid) COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Protein subunit Phase 3 Novavax Inc. 2020 Australia 18 - 59 years 2 doses 21 days apart Intramuscular NA NA NA US FDA NA NA TAK-019, SARS-CoV-2 rS NA NCT04368988 https://clinicaltrials.gov/show/NCT04368988 https://clinicaltrials.gov/ct2/show/NCT04368988
10353 COVIVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Instituto Butantan 2020 Brazil 18 years and above 2 doses 2 weeks apart Intramuscular NA NA NA NA NA NA ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac NA NCT04456595 https://clinicaltrials.gov/show/NCT04456595 NA
10354 SCTV01C COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Subunit vaccine Phase 3 Sinocelltech Ltd. 2021 China 18 years and above 2 doses 14 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT05043311 http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5890 NA
10355 CoviVac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Inactivated Phase 3 Chumakov Centre at the Russian Academy of Sciences 2021 Russia 18 - 60 years 2 doses 14 days apart Intramuscular NA Inactivated SARS-CoV-2 virus NA NA NA NA NA NA NA https://www.precisionvaccinations.com/vaccines/covivac-russia-covid-19-vaccine NA
10356 V70P5 Influenza (flu) Respiratory Influenza virus positive-sense, single-stranded RNA Inactivated Phase 3 Novartis 2015 USA 6 months - 71 months 2 doses Intramuscular NA Inactivated Influenza virus NA NA NA NA NBP607 NA NCT00644059 https://clinicaltrials.gov/ct2/show/NCT00644059?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=14 NA
10357 NBP607-QIV Influenza (flu) Respiratory Influenza virus positive-sense, single-stranded RNA Inactivated Phase 3 SK Chemicals Co. Ltd. 2015 South Korea 6 months - 18 years 1- 2 doses depending on volume and age Intramuscular NA Inactivated Influenza virus Cell culture based NA NA NA NA NA NCT02914275 https://clinicaltrials.gov/ct2/show/NCT02914275?recrs=ade&cond=Influenza%2C+Human&phase=23&draw=2&rank=18 NA
10358 Seqirus QIV Influenza (flu) Respiratory Influenza virus positive-sense, single-stranded RNA Inactivated Phase 3 Seqirus 2019 USA 6 months - 59 months 1- 2 doses depending on volume and age Intramuscular NA Four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season NA US FDA NA NA NA NA NCT02914275 https://www.clinicaltrials.gov/ct2/show/NCT02914275 NA
10359 RSV F vaccine Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA Live-attenuated Phase 3 Novavax Inc. 2020 USA 18 - 40 years 2 doses 9 months apart Intramuscular Aluminum RSV surface glycoprotein NA NA Bill and Melinda Gates Foundation NA NA NA NCT02624947 https://clinicaltrials.gov/ct2/show/NCT02624947?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=2 NA
10360 Motavizumab Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA Protein subunit Phase 3 MedImmune LLC 2013 USA upto 1 year 5 doses in interval for 1 month Intramuscular NA Fusion glycoprotein of RSV NA NA NA NA NA NA NCT00129766 https://clinicaltrials.gov/ct2/show/NCT00129766?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=3 NA
10361 Ad26. RSV. preF Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA Recombinant viral vector Phase 3 Janssen Pharmaceutical 2021 USA 18 - 59 years 2 doses 6 months apart Intramuscular NA Fusion glycoprotein of RSV NA US FDA NA NA NA NA NCT05070546 https://clinicaltrials.gov/ct2/show/NCT05070546?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=8 https://www.fda.gov/media/105619/download
10362 MK-1654 Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA NA Phase 3 Merck & Co. Inc. 2021 USA upto 1 year NA Intramuscular NA Fusion glycoprotein of RSV NA US FDA NA NA NA NA NCT04938830 https://clinicaltrials.gov/ct2/show/NCT04938830?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=12 https://ichgcp.net/clinical-trials-registry/NCT04938830
10363 STAMARiL Yellow fever Hemorrhagic Yellow fever virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Sanofi Pasteur NA France 10 months Single dose Subcutaneous NA 17D-204 strain of yellow fever virus Produced in specified pathogen-free chick embryos NA NA NA NA NA NA https://www.sanofipasteur.co.uk/-/media/ems/conditions/vaccines/brands/oneportal-ie/pdf/105_stamaril_mah_address_update_12_2017_uk.pdf NA
10364 TAK-003 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Takeda Pharmaceutical Company Limited NA USA 4 - 16 years NA Subcutaneous NA Dengue virus serotypes (1, 2, 3 and 4) Mammalian cell vero culture NA NA NA TDV 30684747 NA https://www.sciencedirect.com/science/article/pii/S1201971219300402 NA
10365 TV-003/005 Dengue fever Hemorrhagic Dengue virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Merck & Co. Inc. NA Brazil 2 - 59 years NA Subcutaneous NA Dengue virus serotypes (1, 2, 3 and 4) Mammalian cell vero culture NA National Institute of Allergy and Infectious Diseases NA TetraVax-DV 30684747 NCT02406729 https://www.sciencedirect.com/science/article/pii/S1201971219300402 https://clinicaltrials.gov/ct2/show/NCT02406729
10366 EPAXAL Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Inactivated Phase 3 Crucell, Berna Biotech NA Berne, Switzerland NA P: 24 U; Adults: 24 U Intramuscular NA RG-SB NA NA NA NA NA 29661808 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/ NA
10367 Aimugen Hepatitis A Hepatitic Hepatitis A virus positive-sense, single-stranded RNA Inactivated Phase 3 Chemo-Sero-Therapeutic Research Institute NA Japan NA P: 0.5 µg; Adults: 0.5 µg Intramuscular Aluminum (aluminium hydroxide) KRM003 NA NA NA NA NA 29661808 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360863/ NA
10368 Hepatyrix Hepatitis A, Typhoid Hepatitic Hepatitis A virus, Salmonella typhi double stranded DNA Inactivated Phase 3 Sanofi Pasteur 2015 Belgium 15 years and above Single dose Intramuscular NA Hepatitis A viral protein along with Vi polysaccharide antigen (a part of the Salmonella typhi (Ty2 strain) bacterium NA NA NA NA NA NA NA https://www.hpra.ie/img/uploaded/vaccines/PIL_PA1077099001.pdf NA
10369 SYN023 (Freeze-dried Rabies Vaccine for Human Use (Vero Cells)) Rabies Neurologic Rabies virus negative-sense, single-stranded RNA NA Phase 3 Synermore Biologics (Suzhou) Co. Ltd. 2020 China 18 years and above 5 doses on day 1, 4, 8, 15 and 29 Intramuscular NA NA NA US FDA Simoon Record Pharma Information Consulting Co. Ltd., Clinchoice Inc. NA NA NA NCT04644484 https://clinicaltrials.gov/ct2/show/NCT04644484?cond=Rabies+Human&phase=23&draw=2&rank=4 NA
10370 JE-VAX Viral encephalitis Neurologic West Nile virus positive-sense, single-stranded RNA Live-attenuated Phase 3 Research Foundation for Microbial Diseases of Osaka University NA China NA NA Subcutaneous NA Nakayama-NIH/Beijing-1(P1) strain Mouse brain based NA NA Asia SA 14-14-2 vaccine 24161909 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185882/ NA
10371 Simplirix Genital Herpes Cutaneous Herpes simplex virus double stranded DNA Subunit vaccine Phase 3 GlaxoSmithKline 2008 UK 18 - 30 years NA Intraperitoneal 3-deacylated form of MPL, alum Herpes simplex virus 2 glycoprotein D (gD-2) NA NA National Institute of Allergy and Infectious Diseases NA NA NA NCT00057330 https://www.precisionvaccinations.com/vaccines/herpes-vaccine-candidates, https://clinicaltrials.gov/ct2/show/NCT00057330 NA
10372 Sf21-VLP (PXVX0317) Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Virus like particle Phase 3 Emergent BioSolutions 2021 NA 12 - 65 years NA NA Alhydrogel NA Virus-like particle made using baculovirus and Sf21 insect cells US FDA NA NA NA NA NCT05072080 https://link.springer.com/chapter/10.1007/82_2019_175 https://clinicaltrials.gov/ct2/show/NCT05072080
10373 PENN CHIKV-2008 (PC-08) Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA DNA based vaccine Phase 3 University of Pennsylvania 2011 USA NA NA NA NA CHIKV envelope proteins (E1, E2, and E3) NA NA NA NA NA NA NA https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019110/
10374 MRVAC Measles, Rubella Exanthous Morbillivirus, Rubella virus negative-sense, single-stranded RNA Live-attenuated Phase 3 Center for Research and Production of Vaccines and Biologicals 2018 Vietnam 1 - 45 years NA Subcutaneous NA Strain AIK-C measles virus clone with Takahashi rubella virus NA NA NA NA NA NA NCT03713359 https://clinicaltrials.gov/ct2/show/NCT03713359?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=54 NA